TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2508417
Drug: Triphasic oral
Normalized name: CeeNU, triphasic oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triphasic oral contraceptive containing ethinylestradiol and gestodene
Study: 31562800
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus veliparib followed by veliparib maintenance (veliparib throughout)
Study: 31562800
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus veliparib followed by placebo maintenance (veliparib combination only)
Study: 31562800
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus placebo followed by placebo maintenance (control)
Study: 31562800
Drug: Chemotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy plus veliparib
Study: 28526486
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patches (50 μg hour−1)
Study: 28526486
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patches (75 μg hour−1)
Study: 28526486
Drug: Fentanyl transdermal
Normalized name: Fentanyl Transdermal System
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl transdermal patches (100 μg hour−1)
Study: 28526486
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal patches (35 μg hour−1)
Study: 28526486
Drug: Buprenorphine transdermal
Normalized name: Buprenorphine Transdermal System
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Buprenorphine transdermal patches (70 μg hour−1)
Study: 21272992
Drug: Intravesical administration
Normalized name: Valrubicin Intravesical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravesical administration of hyaluronic acid (HA) and chondroitin sulphate (CS)
Study: 11518093
Drug: 15-mg nicotine
Normalized name: nicotine
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 15-mg nicotine patch (16-hr)
Study: 3115389
Drug: Stable strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable strontium absorption test with standard breakfast
Study: 3115389
Drug: Stable strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable strontium absorption test
Study: 3115389
Drug: Stable strontium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stable strontium absorption test with food
Study: 29953026
Drug: Active laser
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Active laser therapy (wavelength: 780 nm; fluence: 134 J/cm; power: 50 mW; irradiance: 1.675 W/cm; exposure time: 80 seconds per point) on 3 points of the masseter and 1 point on the anterior temporal muscles on each side
Study: 26749451
Drug: Alfacalcidol (0.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alfacalcidol (0.25 μg daily for six months)
Study: 23422606
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of 2/3 (10.6 mm) of the total root length (G1 - control)
Study: 23422606
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of 1/2 (8 mm) of the total root length (G2)
Study: 23422606
Drug: Preparation of
Normalized name: kit for the preparation of Ga-68
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preparation of 1/3 (5.3 mm) of the total root length (G3)
Study: 20177860
Drug: Standardized 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standardized 200 ml of clear carbohydrate‐enriched drink orally 2 hours before surgery
Study: 16614691
Drug: Lysine clonixinate
Normalized name: lysine clonixinate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lysine clonixinate (LC) 250 mg
Study: 16614691
Drug: Naproxen sodium
Normalized name: Naproxen Sodium
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen sodium (NS) 550 mg
Study: 12638395
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg single dose
Study: 12638395
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg multiple doses (once daily for 10 days)
Study: 12638395
Drug: Etoricoxib 120
Normalized name: etoricoxib 120 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etoricoxib 120 mg with high-fat meal
Study: 7112816
Drug: Catheters changed
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Catheters changed monthly as well as for infection and/or obstruction
Study: 30515573
Drug: Telephone-based reminiscence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telephone-based reminiscence therapy (TBR)
Study: 28742260
Drug: Optimal individualized
Normalized name: Optima Plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimal individualized treatment rule using preference elicitation questionnaire and item response theory
Study: 26733563
Drug: Vitamin K3
Normalized name: Vitamin K3
DrugBank: Menadione (DB00170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin K3 acupuncture point injection
Study: 26733563
Drug: Saline acupuncture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Saline acupuncture point injection
Study: 26733563
Drug: Vitamin K3
Normalized name: Vitamin K3
DrugBank: Menadione (DB00170)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin K3 deep muscle injection
Study: 19158211
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg folic acid daily for 30 weeks
Study: 19158211
Drug: 1.1 mg
Normalized name: menthol 1.1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.1 mg folic acid daily for 30 weeks
Study: 15101069
Drug: CD-ROM cognitive-behavioral
Approvals — FDA: no, EMA: no, PMDA: no
Description: CD-ROM cognitive-behavioral self-help treatment (8 sessions)
Study: 8592249
Drug: Imidapril hydrochloride
Normalized name: imidapril hydrochloride
DrugBank: Imidapril (DB11783)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imidapril hydrochloride (5 mg once a day, increased to 10 mg if necessary)
Study: 8592249
Drug: Enalapril maleate
Normalized name: Enalapril Maleate
DrugBank: Enalapril (DB00584)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Enalapril maleate (5 mg once a day, increased to 10 mg if necessary)
Study: 28320991
Drug: Risk score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Risk score model for contrast-induced nephropathy (CIN) based on age > 75 years, creatinine clearance (CrCl) < 60 mL/minute, and congestive heart failure (CHF)
Study: 23421487
Drug: Diesel exhaust
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diesel exhaust (DE) exposure at 100 μg/m³ PM₁₀ for 2 hours
Study: 19332035
Drug: Various pharmacological
Normalized name: various
Approvals — FDA: no, EMA: no, PMDA: no
Description: Various pharmacological agents including antidepressants, anti-adrenergic agents, anticonvulsants, benzodiazepines, atypical antipsychotics, and novel agents
Study: 9456189
Drug: Epirubicin 130
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epirubicin 130 mg/m2 every 3 weeks until disease progression or cumulative dose of 1000 mg/m2 or heart failure occurred
Study: 7856686
Drug: One subdermal
Normalized name: Gel-One
Approvals — FDA: no, EMA: no, PMDA: no
Description: One subdermal estradiol implant
Study: 7856686
Drug: Three subdermal
Normalized name: three-lobe sage extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Three subdermal estradiol implants
Study: 7856686
Drug: Both groups
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both groups (one and three implants)
Study: 2159054
Drug: Intravenous vindesine
Normalized name: vindesine
DrugBank: Vindesine (DB00309)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous vindesine (V) 3 mg/m2 every 2 weeks
Study: 2159054
Drug: V 3
Normalized name: Ruta Grav 30X
Approvals — FDA: no, EMA: no, PMDA: no
Description: V 3 mg/m2 weekly for 5 weeks plus mitomycin (VM) 20 mg/m2 day 1 and then 15 mg/m2 every 6 weeks
Study: 2159054
Drug: V at
Normalized name: Penicillin V
DrugBank: Phenoxymethylpenicillin (DB00417)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: V at the more intensive dose rate plus cisplatin (VC) 120 mg/m2 with forced diuresis on days 1 and 29 and then every 6 weeks
Study: 31095724
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (EVLA, dRFA, iRFA)
Study: 25264565
Drug: Flupirtine IR
Normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine IR (100 mg)
Study: 25264565
Drug: Flupirtine MR
Normalized name: FLUPIRTINE
DrugBank: Flupirtine (DB06623)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flupirtine MR (400 mg once daily for 8 days)
Study: 21353585
Drug: Warm-blood cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm-blood cardioplegia supplemented with 16 mmol l⁻¹ Mg²⁺
Study: 21353585
Drug: Warm-blood cardioplegia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Warm-blood cardioplegia supplemented with 5 mmol l⁻¹ Mg²⁺
Study: 19596563
Drug: Aerosol provocation
Normalized name: tetracaine
DrugBank: Tetracaine (DB09085)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aerosol provocation system (APS) using a single concentration of 16mg/mL methacholine (APS-SC)
Study: 15271108
Drug: Practice style
Approvals — FDA: no, EMA: no, PMDA: no
Description: Practice style embodying traditional geriatric principles of care (prescribing no high-risk medications)
Study: 11405513
Drug: Hydrocortisone 200
Normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Hydrocortisone 200 mg intravenously prior to salbutamol
Study: 1295808
Drug: Growth hormone
Normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Growth hormone (GH) co-treatment
Study: 31597083
Drug: XC8 (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC8 (10 mg)
Study: 31597083
Drug: XC8 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC8 (50 mg)
Study: 31597083
Drug: XC8 (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC8 (200 mg)
Study: 31597083
Drug: XC8 (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: XC8 (all doses)
Study: 30293349
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) for MMAF patients
Study: 30293349
Drug: Intracytoplasmic sperm
Normalized name: herring sperm DNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracytoplasmic sperm injection (ICSI) for OA patients
Study: 22117732
Drug: Moderately rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderately rough implants (TiUnite)
Study: 22117732
Drug: Minimally rough
Normalized name: rough marshelder pollen extract
DrugBank: Iva annua pollen (DB10927)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimally rough implants (turned)
Study: 21048171
Drug: Radial shock-wave
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radial shock-wave therapy (Group II, n = 48)
Study: 7326866
Drug: Dexamethasone acetate
Normalized name: Dexamethasone Acetate
DrugBank: Dexamethasone acetate (DB14649)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexamethasone acetate at 2 of 3 mg/day for 9 or 13 weeks
Study: 24969283
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of rifaximin twice a day for 12 weeks
Study: 24969283
Drug: 800 mg
Normalized name: bran 800 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg of rifaximin
Study: 17502725
Drug: Immediate PAIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate PAIG injections (weeks 0 and 6)
Study: 17502725
Drug: Delayed PAIG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed PAIG injections (weeks 12 and 18)
Study: 17502725
Drug: Both immediate
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both immediate and delayed PAIG injections
Study: 9932756
Drug: Patient-controlled sedation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient-controlled sedation using propofol (10 mg/ml) and alfentanil (25 microg/ml)
Study: 9932756
Drug: Intravenous diazemuls
Normalized name: Diazemuls
DrugBank: Diazepam (DB00829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous diazemuls (10-20 mg) and pethidine (50 mg)
Study: 7804031
Drug: Selenium concentration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium concentration and glutathione peroxidase activity before and during treatment with cytostatics
Study: 2231320
Drug: Immediate-release (IR)
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate-release (IR) hydralazine thrice daily, daily doses of 75, 150, or 300 mg
Study: 2231320
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) hydralazine twice daily, daily doses of 75, 150, or 300 mg
Study: 2231320
Drug: Extended-release (ER)
Normalized name: Extended Release Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended-release (ER) hydralazine once daily, daily doses of 75, 150, or 300 mg
Study: 2231320
Drug: Concomitant beta-blocker
Normalized name: Beta Carotene
DrugBank: Beta carotene (DB06755)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant beta-blocker (BB) therapy
Study: 2231320
Drug: Hydralazine treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydralazine treatment
Study: 31481362
Drug: Music therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Music therapy (MT) focusing on parental singing tailored to infant responses during NICU and/or postdischarge 6-month period
Study: 29947285
Drug: Ginger aromatherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ginger aromatherapy (inhalation of essential oil of ginger)
Study: 27816672
Drug: CC (41
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC (41 participants)
Study: 27816672
Drug: THS 2.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: THS 2.2 and CC (80 and 41 participants respectively)
Study: 24268387
Drug: omega-3 (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: omega-3 (1 g, 3 times daily)
Study: 22902139
Drug: Instrument-assisted spinal
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Instrument-assisted spinal manipulative therapy (SMT)
Study: 20230454
Drug: 240 mg
Normalized name: aspirin 240 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 240 mg lidocaine in 125 mL of saline once a week for 4 weeks
Study: 18942422
Drug: New Russian
Approvals — FDA: no, EMA: no, PMDA: no
Description: New Russian oral ribavirin-containing agents
Study: 2082489
Drug: Aspirin (330
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (330 mg) and dipyridamole (75 mg) t.i.d.
Study: 7436817
Drug: Sinemet 20/100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet 20/100 (20 mg of carbidopa to 100 mg of levodopa)
Study: 7436817
Drug: Sinemet 10/100
Normalized name: Sinemet 10/100 Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sinemet 10/100 (10 mg of carbidopa to 100 mg of levodopa)
Study: 7436817
Drug: Levodopa alone
Normalized name: Levodopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Levodopa alone (100 mg)
Study: 31192423
Drug: Multimodal occupational
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multimodal occupational specific treatment for exhaustion disorder
Study: 28129020
Drug: Brinzolamide/Brimonidine Fixed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Brinzolamide/Brimonidine Fixed Combination (BBFC) 1%/0.2% 3 times daily
Study: 11384568
Drug: Timolol maleate
Normalized name: Timolol Maleate
DrugBank: Timolol (DB00373)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Timolol maleate 0.5% twice daily
Study: 25905534
Drug: Hot glutamate
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Hot glutamate solution (48°C)
Study: 25905534
Drug: Cold glutamate
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cold glutamate solution (3°C)
Study: 25905534
Drug: Isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isotonic saline (neutral solution at 36°C)
Study: 25905534
Drug: Cold solutions
Normalized name: menthol Topical Solution [Cold Spot]
DrugBank: Chlorpheniramine (DB01114)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cold solutions
Study: 21343835
Drug: Low-dose ZENPEP
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ZENPEP (7 × 5000 lipase units per day)
Study: 21343835
Drug: High-dose ZENPEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ZENPEP (7 × 20,000 lipase units per day)
Study: 21343835
Drug: High-dose ZENPEP
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ZENPEP (7 × 20,000 lipase units per day) in patients with baseline CFA < 90% (n = 33)
Study: 21343835
Drug: Both doses
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both doses of ZENPEP
Study: 594788
Drug: Methyclothiazide 10
Normalized name: Methyclothiazide
DrugBank: Methyclothiazide (DB00232)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyclothiazide 10 mg daily
Study: 594788
Drug: Methyclothiazide 5
Normalized name: methyclothiazide 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methyclothiazide 5 mg daily
Study: 21309619
Drug: Combined psycho-
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psycho- and pharmacotherapy for patients with co-morbid personality disorders (PDs)
Study: 21309619
Drug: Combined psycho-
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined psycho- and pharmacotherapy for patients with no personality disorders (PDs)
Study: 16499796
Drug: 0.75% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% hyperbaric bupivacaine 1.5 ml with 0.25 ml fentanyl (12.5 microg)
Study: 16499796
Drug: 0.75% hyperbaric
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.75% hyperbaric bupivacaine 1.5 ml with 0.25 ml normal saline
Study: 14679137
Drug: Temozolomide 200
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 200 mg/m2/day
Study: 14679137
Drug: Temozolomide 250
Normalized name: temozolomide 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide 250 mg/m2/day
Study: 14679137
Drug: Temozolomide 300
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 300 mg/m2/day
Study: 14679137
Drug: Temozolomide 350
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 350 mg/m2/day
Study: 14679137
Drug: Temozolomide 300
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide 300 mg/m2/day recommended dose
Study: 14679137
Drug: Temozolomide (dose-dense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Temozolomide (dose-dense regimen)
Study: 11704117
Drug: Ibuprofen (800
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (800 mg, three times per day for 10 days)
Study: 3134518
Drug: Antihypertensive treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antihypertensive treatment (beta-blocker)
Study: 30144146
Drug: Low Oral
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Oral Health Literacy (OHL) defined as BREALD-30 ≤ 21
Study: 30144146
Drug: Low Oral
Normalized name: Milkflow oral capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low Oral Health Literacy (OHL)
Study: 30144146
Drug: Higher Oral
Normalized name: BENZOCAINE 50 mg in 1 mL TOPICAL GEL [HIGHER CONTROL Male Climax Control Lubricating]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher Oral Health Literacy (OHL)
Study: 28795232
Drug: Conventional Doyle
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional Doyle intranasal silicone splint (Group 1)
Study: 24002152
Drug: Topical adapalene
Normalized name: adapalene Topical Gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical adapalene 0.1% gel
Study: 24002152
Drug: Topical benzoyl
Normalized name: benzoyl peroxide Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical benzoyl peroxide 2.5% gel
Study: 21359582
Drug: Insulin during
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin during hospitalisation followed by conventional glucose control (group 2)
Study: 21359582
Drug: Conventional treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional treatment (group 3)
Study: 14594526
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg for 20 weeks
Study: 14594526
Drug: Pioglitazone 30
Normalized name: pioglitazone 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 30 mg for 12 weeks followed by 45 mg for 8 weeks
Study: 14594526
Drug: Pioglitazone 45
Normalized name: pioglitazone 45 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pioglitazone 45 mg for 20 weeks
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose level I (60/30 mg/kg/day)
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose level II (120/60 mg/kg/day)
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose level III (120/90 mg/kg/day)
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose level IV (120/120 mg/kg/day)
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose levels I and II
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose levels III and IV
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose levels I-II
Study: 10918402
Drug: Foscarnet at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet at dose levels III-IV
Study: 10918402
Drug: Foscarnet (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Foscarnet (all dose levels)
Study: 3911735
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide plus 5 mg amiloride (HCTZ/A)
Study: 3911735
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg hydrochlorothiazide plus 26 mmol potassium chloride (HCTZ/K)
Study: 3911735
Drug: HCTZ/K (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ/K (double dose: 100 mg/52 mmol)
Study: 3911735
Drug: HCTZ/A (double
Approvals — FDA: no, EMA: no, PMDA: no
Description: HCTZ/A (double dose: 100 mg/10 mg)